A Multi-country, Multi-centre, Non-interventional, REtrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate Cancer - REMPRO Registry

AstraZeneca Pharma India Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年4月1日

试验速览

暂无简介。

•1. Male patients = 18 years of age OR legal age of being an adult in the country as per local
•regulations
•2. Patient or next of kin/legal representative (for deceased patients at study entry, unless a
•waiver is granted) willing and able to provide written informed consent according to the
•local regulations
•3. Patients with a diagnosis of metastatic (stage IV) mCRPC, confirmed by either biopsy of a
•metastatic tumour site, or by history of biopsy-proven localized disease and evidence of
•metastatic disease on imaging studies (which is clearly noted in hospital/clinical records)
•and progression on ADT alone between 01 January 2016 and 31 December 2018
•4. Availability of medical records at the participating site reflecting at least one LOT
•received and at least 12 months of follow-up from the index date (unless the patient
•died/lost to follow-up within the first 12 months after diagnosis)

•1. Patients with a concomitant cancer at the time of diagnosis of mCRPC or those who are
•treated with any anti-cancer therapy indicated for other cancers within 6 months of
•diagnosis of mCRPC, except for non-metastatic non-melanoma skin cancers or in situ or
•benign neoplasms.
•2. Patients unable to give an informed consent (unless a waiver is granted)

发起方